[Clinical features and treatment outcome of patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis] [0.03%]
[非霍奇金淋巴瘤相关噬血细胞综合征的临床特点和治疗结局分析]
S R Sun,M Wu,Fulati Wulipan et al.
S R Sun et al.
Objective: To investigate the clinical features and effect of prognostic factors in patients with different pathological types of non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis. Methods: We collected and analyzed the cli...
[CART therapy followed by allo-HSCT for patients with B-cell acute lymphoblastic leukemia relapsing after the first hematopoietic stem cell transplantation] [0.03%]
首次造血干细胞移植后复发的B细胞急性淋巴细胞白血病患者行CAR-T治疗后再用allo-HSCT治疗
X Y Cao,L Y Qiu,J P Zhang et al.
X Y Cao et al.
Objective: To study the clinical efficacy of chimeric antigen receptor T-cell (CART) treatment followed by a second allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with B-cell acute lymphoblastic leukemia (ALL) wh...
[Rare thalassemia caused by novel nucleotide variants in the globin gene: four case reports and literature review] [0.03%]
新型珠蛋白基因核苷酸变异所致罕见地中海贫血4例报告及文献复习
Z Z Da,L H Chen,H M Jiang et al.
Z Z Da et al.
Objective: To analyze the DNA sequences and clinical phenotypes of four cases with rare thalassemia to improve its recognition and accurate diagnosis. Methods: The DNA sequence characteristics of four cases with rare thalassemia diagnosed f...
[Familial platelet disorder with predisposition to myeloid leukemia (FPD/AML): a case report and literature review] [0.03%]
[灰质瘤合并血小板病易患粒细胞白血病家系的临床特征及遗传学研究]
R R Zhang,X J Chen,Y Y Ren et al.
R R Zhang et al.
Objective: To analyze the clinical features, bone marrow features, and gene mutations of children with familial platelet disorder with predisposition to myeloid leukemia (FPD/AML) caused by a RUNX1 germline mutation as well as their family ...
D L Zhang,F Xue,X Q Dou et al.
D L Zhang et al.
Objective: To analyze the clinical phenotype and molecular pathogenesis of nine patients with hereditary factor Ⅴ (FⅤ) deficiency. Methods: Nine patients with hereditary FⅤ deficiency who were admitted to the Institute of Hematology and ...
[Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10] [0.03%]
骨髓单克隆浆细胞比例小于10%的36例新诊断多发性骨髓瘤患者的临床特征及预后分析
J T Zhao,X Y Jiang,C Yang et al.
J T Zhao et al.
Objective: To improve the understanding of newly diagnosed multiple myeloma (NDMM) patients with bone marrow (BM) monoclonal plasma cell ratio of less than 10%. Methods: The clinical characteristics, laboratory examination, response to trea...
[Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial] [0.03%]
[低剂量阿糖胞苷联合维奈克拉治疗不适合强化疗的初诊急性髓系白血病患者的中国人群队列III期随机双盲安慰剂对照试验结果]
Y Hu,J Jin,Y Zhang et al.
Y Hu et al.
Objective: To investigate the safety and efficacy of venetoclax with low-dose cytarabine (LDAC) in Chinese patients with acute myeloid leukemia (AML) who are unable to tolerate intensive induction chemotherapy. Methods: Adults ≥ 18 years w...
Randomized Controlled Trial
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2021 Apr 14;42(4):288-294. DOI:10.3760/cma.j.issn.0253-2727.2021.04.004 2021
[Chinese expert consensus on paroxysmal nocturnal hemoglobinuria detection via flow cytometry (2021)] [0.03%]
中国血细胞分析仪液态悬浮芯片技术PNH检测专家共识(2021)
Cell Analysis Committee, Chinese} Society of Biotechnology;Clinical Flow Cytometry Group, Blood Immune Committee et al.
Cell Analysis Committee et al.
[Chinese expert consensus on the management of hemorrhagic complications after hematopoietic stem cell transplantation(2021)] [0.03%]
[中国造血干细胞移植后出血并发症管理专家共识（2021）]
Chinese Society of Hematology, Chinese Medical Association
Chinese Society of Hematology
[Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021)] [0.03%]
中国慢性移植物抗宿主病诊断和治疗共识(2021)
Hematopoietic Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association;China Association for the Prevention of Hematology Diseases
Hematopoietic Stem Cell Application Group